SCHEMBL200879

SCHEMBL200879

CCCc1ccc(-c2ccccc2C(=O)N2CC[C@H](NC=O)[C@H]2C(=O)NO)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 4/20 0.38
HCRTR2 O43614 4/20 0.38
MMP13 P45452 3/20 0.35
MMP2 P08253 2/20 0.35
MMP9 P14780 1/20 0.35
CHRNB2 P17787 2/20 0.35
CHRNB4 P30926 2/20 0.35
CHRNA3 P32297 2/20 0.35
CHRNA4 P43681 2/20 0.35
CYP3A4 P08684 2/20 0.35
MLNR O43193 1/20 0.35
MMP8 P22894 1/20 0.35
MMP12 P39900 1/20 0.35
SCN1A P35498 1/20 0.34
SCN2A Q99250 1/20 0.34
SCN3A Q9NY46 1/20 0.34
LMNA P02545 1/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202594 0.90 HCRTR1 (0.39) HCRTR1HCRTR2MMP13MMP2MMP9
SCHEMBL200750 0.89 HCRTR1 (0.39) HCRTR1HCRTR2CHRNB2CHRNB4CHRNA3
SCHEMBL203236 0.86 MMP13 (0.38) HCRTR1HCRTR2MMP13MMP2MMP9
SCHEMBL201878 0.85 HCRTR1 (0.38) HCRTR1HCRTR2MMP13MMP2MMP9
SCHEMBL2693118 0.85 MMP2 (0.39) MMP13MMP2MMP9MMP8MMP1
SCHEMBL201008 0.85 HCRTR1 (0.38) HCRTR1HCRTR2MMP13CYP3A4MLNR
SCHEMBL202856 0.85 HCRTR1 (0.38) HCRTR1HCRTR2MMP13CYP3A4MLNR
SCHEMBL201630 0.83 LMNA (0.38) HCRTR1HCRTR2MMP13MMP9CYP3A4
SCHEMBL203250 0.83 LMNA (0.38) HCRTR1HCRTR2MMP13MMP9CYP3A4
SCHEMBL202992 0.83 HCRTR1 (0.40) HCRTR1HCRTR2CYP3A4MLNRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 HCRTR1 1201/4885HCRTR2 1892/4885MMP13 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.